345 related articles for article (PubMed ID: 30120160)
1. FDA Approval Summary: Vemurafenib for the Treatment of Patients with Erdheim-Chester Disease with the
Oneal PA; Kwitkowski V; Luo L; Shen YL; Subramaniam S; Shord S; Goldberg KB; McKee AE; Kaminskas E; Farrell A; Pazdur R
Oncologist; 2018 Dec; 23(12):1520-1524. PubMed ID: 30120160
[TBL] [Abstract][Full Text] [Related]
2. Vemurafenib for BRAF V600-Mutant Erdheim-Chester Disease and Langerhans Cell Histiocytosis: Analysis of Data From the Histology-Independent, Phase 2, Open-label VE-BASKET Study.
Diamond EL; Subbiah V; Lockhart AC; Blay JY; Puzanov I; Chau I; Raje NS; Wolf J; Erinjeri JP; Torrisi J; Lacouture M; Elez E; Martínez-Valle F; Durham B; Arcila ME; Ulaner G; Abdel-Wahab O; Pitcher B; Makrutzki M; Riehl T; Baselga J; Hyman DM
JAMA Oncol; 2018 Mar; 4(3):384-388. PubMed ID: 29188284
[TBL] [Abstract][Full Text] [Related]
3. BRAF-Mutated Erdheim-Chester Disease: Profound Response to Vemurafenib Visualized With Serial Multimodality Imaging.
Gray JCR; Kim J; Digianvittorio M; Feeley NK; Scheel PJ; Siegelman SS; Fishman EK; Rowe SP
J Natl Compr Canc Netw; 2020 Jun; 18(6):650-655. PubMed ID: 32502983
[TBL] [Abstract][Full Text] [Related]
4. Dramatic efficacy of vemurafenib in both multisystemic and refractory Erdheim-Chester disease and Langerhans cell histiocytosis harboring the BRAF V600E mutation.
Haroche J; Cohen-Aubart F; Emile JF; Arnaud L; Maksud P; Charlotte F; Cluzel P; Drier A; Hervier B; Benameur N; Besnard S; Donadieu J; Amoura Z
Blood; 2013 Feb; 121(9):1495-500. PubMed ID: 23258922
[TBL] [Abstract][Full Text] [Related]
5. Hypoalphalipoproteinemia and BRAF
Cohen-Aubart F; Guerin M; Poupel L; Cluzel P; Saint-Charles F; Charlotte F; Arsafi Y; Emile JF; Frisdal E; Le Goff C; Donadieu J; Amoura Z; Lesnik P; Haroche J; Le Goff W
Arterioscler Thromb Vasc Biol; 2018 Aug; 38(8):1913-1925. PubMed ID: 29930009
[TBL] [Abstract][Full Text] [Related]
6. An effective treatment in Erdheim Chester disease: vemurafenib: a case report.
Bozan E; Darçın T; Yaman S; Yiğenoğlu TN; Kızıl Çakar M; Dal MS; Altuntaş F
J Med Case Rep; 2023 Oct; 17(1):426. PubMed ID: 37821987
[TBL] [Abstract][Full Text] [Related]
7. Reproducible and sustained efficacy of targeted therapy with vemurafenib in patients with BRAF(V600E)-mutated Erdheim-Chester disease.
Haroche J; Cohen-Aubart F; Emile JF; Maksud P; Drier A; Tolédano D; Barete S; Charlotte F; Cluzel P; Donadieu J; Benameur N; Grenier PA; Besnard S; Ory JP; Lifermann F; Idbaih A; Granel B; Graffin B; Hervier B; Arnaud L; Amoura Z
J Clin Oncol; 2015 Feb; 33(5):411-8. PubMed ID: 25422482
[TBL] [Abstract][Full Text] [Related]
8. The histiocytosis Erdheim-Chester disease is an inflammatory myeloid neoplasm.
Haroche J; Cohen-Aubart F; Charlotte F; Maksud P; Grenier PA; Cluzel P; Mathian A; Emile JF; Amoura Z
Expert Rev Clin Immunol; 2015; 11(9):1033-42. PubMed ID: 26197238
[TBL] [Abstract][Full Text] [Related]
9. [Efficacy and safety of vemurafenib in the treatment of BRAF(V600E)-mutated Erdheim-Chester disease].
Liu T; He TH; Niu N; Li J; Zhou DB; Cao XX
Zhonghua Xue Ye Xue Za Zhi; 2021 Sep; 42(9):752-756. PubMed ID: 34753230
[No Abstract] [Full Text] [Related]
10. Dramatic efficacy of dabrafenib in Erdheim-Chester disease (ECD): a pediatric patient with multiple large intracranial ECD lesions hidden by refractory Langerhans cell histiocytosis.
Hao X; Feng R; Bi Y; Liu Y; Li C; Lu T; Tian Y
J Neurosurg Pediatr; 2018 Sep; 23(1):48-53. PubMed ID: 30265230
[TBL] [Abstract][Full Text] [Related]
11. Real-World Toxicity Experience with BRAF/MEK Inhibitors in Patients with Erdheim-Chester Disease.
Saunders IM; Goodman AM; Kurzrock R
Oncologist; 2020 Feb; 25(2):e386-e390. PubMed ID: 32043767
[TBL] [Abstract][Full Text] [Related]
12. [Erdheim-Chester disease-A histiocytic multisystem disease with unusual renal involvement].
Dasdelen S; Büschek F
Internist (Berl); 2020 Sep; 61(9):969-979. PubMed ID: 32785740
[TBL] [Abstract][Full Text] [Related]
13. Profound systemic alteration of the immune phenotype and an immunoglobulin switch in Erdheim-Chester disease in 78 patients from a single center.
Aubart FC; Poupel L; Saint-Charles F; Charlotte F; Arsafi Y; Frisdal E; Roos-Weil D; Emile JF; Amoura Z; Guerin M; Lesnik P; Haroche J; Le Goff W
Haematologica; 2022 Jun; 107(6):1347-1357. PubMed ID: 34647443
[TBL] [Abstract][Full Text] [Related]
14. FDA approval summary: vemurafenib for treatment of unresectable or metastatic melanoma with the BRAFV600E mutation.
Kim G; McKee AE; Ning YM; Hazarika M; Theoret M; Johnson JR; Xu QC; Tang S; Sridhara R; Jiang X; He K; Roscoe D; McGuinn WD; Helms WS; Russell AM; Miksinski SP; Zirkelbach JF; Earp J; Liu Q; Ibrahim A; Justice R; Pazdur R
Clin Cancer Res; 2014 Oct; 20(19):4994-5000. PubMed ID: 25096067
[TBL] [Abstract][Full Text] [Related]
15. [Status of Langerhans cell histiocytosis in children and adults].
Kudo K
Rinsho Ketsueki; 2019; 60(9):1308-1316. PubMed ID: 31597857
[TBL] [Abstract][Full Text] [Related]
16. Erdheim-Chester disease.
Campochiaro C; Tomelleri A; Cavalli G; Berti A; Dagna L
Eur J Intern Med; 2015 May; 26(4):223-9. PubMed ID: 25865950
[TBL] [Abstract][Full Text] [Related]
17. Erdheim-Chester disease.
Haroche J; Arnaud L; Cohen-Aubart F; Hervier B; Charlotte F; Emile JF; Amoura Z
Rheum Dis Clin North Am; 2013 May; 39(2):299-311. PubMed ID: 23597965
[TBL] [Abstract][Full Text] [Related]
18. [Erdheim-Chester disease (ECD), an inflammatory myeloid neoplasia].
Haroche J; Papo M; Cohen-Aubart F; Charlotte F; Maksud P; Grenier PA; Cluzel P; Mathian A; Emile JF; Amoura Z
Presse Med; 2017 Jan; 46(1):96-106. PubMed ID: 27234902
[TBL] [Abstract][Full Text] [Related]
19. Erdheim-Chester Disease: a Rare but Important Cause of Recurrent Pericarditis.
Chahine J; Alzubi J; Alnajjar H; Ramchand J; Chetrit M; Klein AL
Curr Cardiol Rep; 2020 Jun; 22(8):75. PubMed ID: 32607694
[TBL] [Abstract][Full Text] [Related]
20. Vemurafenib as first-line therapy in
Fernández-Eulate G; Muñoz-Lopetegi A; Ruiz I; Urtasun M
BMJ Case Rep; 2019 Nov; 12(11):. PubMed ID: 31748352
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
